Micronutrients are essential vitamins and minerals that are vital for well-being and disease prevention, but deficiencies can commonly be caused by food allergies and dietary restrictions, certain prescription medications, or chronic health conditions. At least one in three Americans are at risk of nutrient deficiencies1. Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the availability of 13 blood tests designed to evaluate micronutrient deficiencies, helping people identify if they are lacking certain vitamins and minerals needed by the body to maintain optimal health. These panels are now available for consumer purchase exclusively at questhealth.com.

Against the background of the current rapid development of life science and technology, with the development of clinical biochemical test technologies, there are more and more product categories and test items in the biochemical detection platform.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the release of the QIAstat-Dx Analyzer 2.0, including the Software 1.6 upgrade, a significant enhancement to the widely-used QIAstat-Dx Analyzer 1.0 for reliable, fast and cost-effective diagnosis of complex syndromes.

C-luminary Biotech was founded in 2018 and is headquartered in Chengdu, China, with a research and development center in Suzhou and industrial platforms in Sichuan and Hunan, is a professional enterprise engaged in the research, development, production, and sale of in vitro diagnostic products.

Based on more than 6 years' efforts in product development and 4 years' commercial verification inland and overseas, Libbot Bio-tech finally expanded the Tarsee product family and launched an overall solution for gel card-based blood grouping.

With over 40 years of development, China's in vitro diagnostic (IVD) industry has made significant strides, presenting a comprehensive range of products that boast improving quality and surging export demands. The internationalization of IVD products, especially concerning human health, emerges as a pivotal strategy of companies for manufacturing, development, and future growth.

HumaDX Tech Co., Ltd. (abbreviated as "HumaDX") completed its A2 round of financing in the first quarter of this year, with this round jointly invested by Wenrun Investment and Sunland Fund.